{
    "clinical_study": {
        "@rank": "36964", 
        "arm_group": [
            {
                "arm_group_label": "OnabotulinumtoxinA Dose A", 
                "arm_group_type": "Experimental", 
                "description": "OnabotulinumtoxinA Dose A injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses."
            }, 
            {
                "arm_group_label": "OnabotulinumtoxinA Dose B", 
                "arm_group_type": "Experimental", 
                "description": "OnabotulinumtoxinA Dose B injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses."
            }, 
            {
                "arm_group_label": "OnabotulinumtoxinA Dose C", 
                "arm_group_type": "Experimental", 
                "description": "OnabotulinumtoxinA Dose C injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX\u00ae) for the\n      treatment of urinary incontinence due to overactive bladder in pediatric patients between\n      the ages of 12 to 17 years who have not been adequately managed with anticholinergics."
        }, 
        "brief_title": "OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Urinary Incontinence", 
            "Urinary Bladder, Overactive"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Urinary Incontinence", 
                "Urinary Bladder, Overactive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptoms of overactive bladder (OAB) (frequency/urgency) with urinary incontinence\n             for at least 6 months\n\n          -  OAB symptoms not adequately managed by 1 or more anticholinergic agents\n\n        Exclusion Criteria:\n\n          -  OAB caused by a neurological condition\n\n          -  Use of anticholinergics or other medications to treat OAB symptoms within 7 days\n\n          -  Current use of indwelling catheter or clean intermittent catheterization to empty the\n             bladder\n\n          -  Previous or current use of botulinum toxin therapy of any serotype for any urological\n             condition, or treatment with botulinum toxin of any serotype within 3 months for any\n             other condition or use\n\n          -  Myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "108", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097121", 
            "org_study_id": "191622-137", 
            "secondary_id": "2014-000464-17"
        }, 
        "intervention": {
            "arm_group_label": [
                "OnabotulinumtoxinA Dose A", 
                "OnabotulinumtoxinA Dose B", 
                "OnabotulinumtoxinA Dose C"
            ], 
            "description": "OnabotulinumtoxinA injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.", 
            "intervention_name": "OnabotulinumtoxinA", 
            "intervention_type": "Biological", 
            "other_name": [
                "BOTOX\u00ae", 
                "botulinum toxin Type A"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "link": {
            "description": "More Information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anchorage", 
                        "country": "United States", 
                        "state": "Alaska"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tarrytown", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Number of Daily Episodes of Urinary Incontinence", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097121"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Number of Daytime Micturition Episodes", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Change from Baseline in Number of Daytime Urgency Episodes", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Percentage of Patients with Night Time Urinary Incontinence", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Volume Voided Per Micturition", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "measure": "Change from Baseline in the 20-Item Pediatric Incontinence Questionnaire (PinQ) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Percentage of Patients With a Positive Treatment Response on the Modified Treatment Benefit Scale (TBS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 12"
            }, 
            {
                "measure": "Time to Patient Request for Retreatment", 
                "safety_issue": "No", 
                "time_frame": "96 Weeks"
            }, 
            {
                "measure": "Time to Patient Qualification for Retreatment", 
                "safety_issue": "No", 
                "time_frame": "96 Weeks"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}